Chuck Royce acquired 1.27 Million Haemonetics shares worth $123 Million. That's 1.12% of their equity portfolio (4th largest holding). The investor owns 2.62% of the outstanding Haemonetics stock. The first Haemonetics trade was made in Q2 2013. Since then Chuck Royce bought shares seventeen more times and sold shares on eight occasions. The stake costed the investor $104 Million, netting the investor a gain of 18% so far.